QQQ   328.62 (+1.40%)
AAPL   171.27 (+1.65%)
MSFT   289.91 (+1.01%)
META   179.50 (+1.13%)
GOOGL   120.56 (+1.45%)
AMZN   141.69 (+0.75%)
TSLA   886.34 (+3.08%)
NVDA   185.21 (+3.23%)
NIO   20.98 (+0.77%)
BABA   94.46 (-0.43%)
AMD   100.86 (+2.79%)
MU   65.14 (+4.53%)
T   18.22 (+1.00%)
CGC   3.30 (+4.76%)
GE   79.26 (+0.46%)
F   16.14 (+1.96%)
DIS   120.52 (+2.40%)
AMC   24.88 (-2.28%)
PYPL   100.62 (+1.52%)
PFE   50.05 (+3.64%)
NFLX   246.54 (+1.58%)
QQQ   328.62 (+1.40%)
AAPL   171.27 (+1.65%)
MSFT   289.91 (+1.01%)
META   179.50 (+1.13%)
GOOGL   120.56 (+1.45%)
AMZN   141.69 (+0.75%)
TSLA   886.34 (+3.08%)
NVDA   185.21 (+3.23%)
NIO   20.98 (+0.77%)
BABA   94.46 (-0.43%)
AMD   100.86 (+2.79%)
MU   65.14 (+4.53%)
T   18.22 (+1.00%)
CGC   3.30 (+4.76%)
GE   79.26 (+0.46%)
F   16.14 (+1.96%)
DIS   120.52 (+2.40%)
AMC   24.88 (-2.28%)
PYPL   100.62 (+1.52%)
PFE   50.05 (+3.64%)
NFLX   246.54 (+1.58%)
QQQ   328.62 (+1.40%)
AAPL   171.27 (+1.65%)
MSFT   289.91 (+1.01%)
META   179.50 (+1.13%)
GOOGL   120.56 (+1.45%)
AMZN   141.69 (+0.75%)
TSLA   886.34 (+3.08%)
NVDA   185.21 (+3.23%)
NIO   20.98 (+0.77%)
BABA   94.46 (-0.43%)
AMD   100.86 (+2.79%)
MU   65.14 (+4.53%)
T   18.22 (+1.00%)
CGC   3.30 (+4.76%)
GE   79.26 (+0.46%)
F   16.14 (+1.96%)
DIS   120.52 (+2.40%)
AMC   24.88 (-2.28%)
PYPL   100.62 (+1.52%)
PFE   50.05 (+3.64%)
NFLX   246.54 (+1.58%)
QQQ   328.62 (+1.40%)
AAPL   171.27 (+1.65%)
MSFT   289.91 (+1.01%)
META   179.50 (+1.13%)
GOOGL   120.56 (+1.45%)
AMZN   141.69 (+0.75%)
TSLA   886.34 (+3.08%)
NVDA   185.21 (+3.23%)
NIO   20.98 (+0.77%)
BABA   94.46 (-0.43%)
AMD   100.86 (+2.79%)
MU   65.14 (+4.53%)
T   18.22 (+1.00%)
CGC   3.30 (+4.76%)
GE   79.26 (+0.46%)
F   16.14 (+1.96%)
DIS   120.52 (+2.40%)
AMC   24.88 (-2.28%)
PYPL   100.62 (+1.52%)
PFE   50.05 (+3.64%)
NFLX   246.54 (+1.58%)
NASDAQ:HROW

Harrow Health - HROW Stock Forecast, Price & News

$8.47
-0.07 (-0.82%)
(As of 08/12/2022 12:42 PM ET)
Add
Compare
Today's Range
$8.11
$8.47
50-Day Range
$6.39
$8.54
52-Week Range
$5.40
$12.99
Volume
298 shs
Average Volume
42,744 shs
Market Capitalization
$229.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.50

Harrow Health MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
113.4% Upside
$17.50 Price Target
Short Interest
Healthy
3.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Harrow Health in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

780th out of 1,117 stocks

Pharmaceutical Preparations Industry

394th out of 550 stocks

HROW stock logo

About Harrow Health (NASDAQ:HROW) Stock

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Harrow Health Stock Up 11.6 %

Shares of HROW Stock traded up $0.89 on Thursday, hitting $8.54. 116,275 shares of the stock were exchanged, compared to its average volume of 86,342. The company has a current ratio of 6.79, a quick ratio of 6.31 and a debt-to-equity ratio of 7.38. The firm has a market capitalization of $230.84 million, a P/E ratio of -9.30 and a beta of 0.78. The business has a 50-day moving average of $6.99 and a 200 day moving average of $7.07. Harrow Health has a fifty-two week low of $5.40 and a fifty-two week high of $12.99.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on HROW shares. TheStreet cut Harrow Health from a "c-" rating to a "d+" rating in a research note on Thursday, May 19th. B. Riley boosted their target price on Harrow Health from $17.00 to $20.00 and gave the company a "buy" rating in a research note on Friday, May 20th.

Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

HROW Stock News Headlines

Harrow Health, Inc. (HROW)
Harrow Health to Present at Aegis Virtual Conference
Harrow Health Publishes Corporate Transparency Report
Select Medical's (SEM) Rising Stake in Concentra to Aid
Harrow Health Added to the Nasdaq Biotechnology Index
See More Headlines
Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

HROW Company Calendar

Last Earnings
11/09/2021
Today
8/12/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HROW
Employees
182
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.50
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+106.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,010,000.00
Pretax Margin
-28.75%

Debt

Sales & Book Value

Annual Sales
$72.48 million
Cash Flow
$0.07 per share
Book Value
$0.20 per share

Miscellaneous

Free Float
23,671,000
Market Cap
$229.28 million
Optionable
Optionable
Beta
0.78

Key Executives

  • Mr. Mark L. Baum J.D. (Age 49)
    CEO & Chairman
    Comp: $1.07M
  • Mr. Andrew R. Boll C.F.A. (Age 40)
    C.M.A., CFA, CMA, CFO & Corp. Sec.
    Comp: $716.73k
  • Dr. Robert J. Kammer D.D.S. (Age 73)
    Special Advisor
    Comp: $91.88k
  • Mr. John P. Saharek (Age 62)
    Pres of ImprimisRx
    Comp: $621.92k
  • Mr. David Moufarrège
    VP of Technology
  • Jamie Webb
    Director of Communications & Investor Relations
  • Dr. Dennis E Saadeh Pharm.D.
    Chief of Formulation Strategy
  • Dr. Larry M. Dillaha
    Chief Medical Officer
  • Mr. Andrew Livingston
    Chief Innovation Officer













HROW Stock - Frequently Asked Questions

Should I buy or sell Harrow Health stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HROW shares.
View HROW analyst ratings
or view top-rated stocks.

What is Harrow Health's stock price forecast for 2022?

2 equities research analysts have issued 12-month target prices for Harrow Health's shares. Their HROW share price forecasts range from $15.00 to $20.00. On average, they expect the company's share price to reach $17.50 in the next twelve months. This suggests a possible upside of 104.9% from the stock's current price.
View analysts price targets for HROW
or view top-rated stocks among Wall Street analysts.

How have HROW shares performed in 2022?

Harrow Health's stock was trading at $8.64 at the beginning of 2022. Since then, HROW stock has decreased by 1.2% and is now trading at $8.54.
View the best growth stocks for 2022 here
.

When is Harrow Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our HROW earnings forecast
.

How were Harrow Health's earnings last quarter?

Harrow Health, Inc. (NASDAQ:HROW) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.34. The company earned $18.71 million during the quarter, compared to the consensus estimate of $17.27 million. Harrow Health had a positive trailing twelve-month return on equity of 15.04% and a negative net margin of 28.96%. During the same quarter in the previous year, the business posted $0.32 EPS.

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).

What is Harrow Health's stock symbol?

Harrow Health trades on the NASDAQ under the ticker symbol "HROW."

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Ophir Asset Management Pty Ltd (5.48%), Acuitas Investments LLC (1.09%), Anchor Capital Advisors LLC (0.84%), Westside Investment Management Inc. (0.73%), Assenagon Asset Management S.A. (0.49%) and Russell Investments Group Ltd. (0.45%). Insiders that own company stock include David P Kennedy, Opaleye Management Inc, Richard L Md Lindstrom, Richard L Md Lindstrom and Robert J Kammer.
View institutional ownership trends
.

How do I buy shares of Harrow Health?

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harrow Health's stock price today?

One share of HROW stock can currently be purchased for approximately $8.54.

How much money does Harrow Health make?

Harrow Health (NASDAQ:HROW) has a market capitalization of $230.84 million and generates $72.48 million in revenue each year. The company earns $-18,010,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

How many employees does Harrow Health have?

The company employs 182 workers across the globe.

How can I contact Harrow Health?

Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The official website for the company is www.harrowinc.com. The company can be reached via phone at (615) 733-4730, via email at jpatton@harrowinc.com, or via fax at 858-345-1745.

This page (NASDAQ:HROW) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.